## Drug Summary
Thiotepa, also known as Thioplex, is a chemotherapeutic agent belonging to the alkylating group utilized in cancer treatment for over 50 years. Structurally, it is a stable derivative of N,N',N''- triethylenephosphoramide (TEPA). Thiotepa predominantly treats breast cancer, ovarian cancer, bladder cancer, and is additionally used in bone marrow transplantation as a conditioning treatment prior to both allogeneic and autologous hematopoietic progenitor cell transplantation in various hematological diseases, as well as solid tumors in both adults and pediatric patients. The pharmacodynamics of thiotepa involves alkylating DNA by creating irreversible cross-links within DNA, preventing the separation of DNA strands necessary for DNA replication and thus inhibiting cell division. This alkylating action is typically nonspecific and affects cells throughout the body.

## Drug Targets, Enzymes, Transporters, and Carriers
The specific molecular targets of thiotepa are not detailed in the provided data, but its mechanism of action is mainly centered around the alkylation of the guanine bases in DNA strands. As for the enzymes involved, thiotepa is metabolized by Cytochrome P450 enzymes including CYP3A4 and CYP2B6, and also involves interactions with Butyrylcholinesterase (BCHE). These enzymes play a role in the biotransformation and degradation of thiotepa, influencing its pharmacokinetic properties. Data concerning specific transporters and carriers involved in the pharmacokinetics of thiotepa remains unavailable, suggesting a gap in detailed understanding of its molecular transport mechanisms.

## Pharmacogenetics
Thiotepa's efficacy and toxicity can vary due to genetic polymorphisms, particularly in the genes encoding for its metabolizing enzymes like CYP3A4 and CYP2B6. Variants in CYP3A4 and CYP2B6 may affect the metabolism rate of thiotepa, potentially altering its toxicity and therapeutic effects. Enhanced activity or overexpression of these enzymes might lead to reduced drug effectiveness due to increased clearance, while reduced enzymatic activity could increase the risk of toxicity due to accumulation of the drug. As specific pharmacogenetic data for thiotepa is not provided in the available resources, these effects are inferred based on general pharmacogenetic principles involving enzymes known to metabolize other alkylating agents. Further research and detailed pharmacogenetic profiling could aid in optimizing dosing and minimizing adverse effects associated with thiotepa therapy.